$13.10
▼ -0.3% Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Overview
52-week range
$9.40
$32
17% of range
Avg surprise (last 3)
-11.9%
Avg reaction (last 2)
+1.0%
100% positive
Latest IV / EM
119%
EM ±18.6% · $13 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-2.44 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-2.93 | $-2.38 | -23.1% | -3.2% | +0.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-3.59 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-3.86 | $-3.10 | -24.5% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-2.84 | $-3.23 | +12.1% | — | +1.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-22.68 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1920.85 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-535.72 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-38.63 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-49.23 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-3.21 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $7M | — | $3M | $2M | $2M | — | $3M |
| Cost of revenue | $703,000 | $2M | — | $1M | $3M | $943,000 | — | $2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-43M | $-42M | — | $-33M | $-28M | $-16M | — | $-16M |
| Net income | $-41M | $-40M | — | $-32M | $-28M | $-17M | — | $-14M |
| EPS (diluted) | $-2.44 | $-2.93 | — | $-3.59 | $-3.86 | $-2.84 | — | $-22.68 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $176M | $185M | $208M | $190M | $125M | $132M | $99M | $28M |
| Inventory | — | — | — | — | — | — | — | $8M |
| Total current assets | $203M | $207M | $229M | $208M | $144M | $150M | $119M | $51M |
| Total assets | $254M | $258M | $277M | $252M | $187M | $193M | $163M | $95M |
| Long-term debt | — | — | — | — | — | — | $5M | $5M |
| Total liabilities | $32M | $31M | $32M | $21M | $19M | $12M | $23M | $21M |
| Total equity | $222M | $227M | $245M | $231M | $168M | $180M | $140M | $74M |